Literature DB >> 1718744

Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes.

C Nahmias1, N Blin, J M Elalouf, M G Mattei, A D Strosberg, L J Emorine.   

Abstract

The gene encoding the murine beta 3-adrenergic receptor (beta 3AR) has been isolated. It translates into a polypeptide of 388 amino acid residues which shows 82% overall homology with the human beta 3AR. In Southern blot experiments, a probe derived from the murine beta 3AR gene hybridizes to a unique restriction fragment in the murine and human genomes. In both species, the beta 3AR gene is located on chromosome 8, in regions (8A2----8A4 in mouse, and 8p11----8p12 in man) which are conserved between mouse and man. The pharmacological profile of the mouse beta 3AR strongly resembles that of the human beta 3AR. It is characterized by a low affinity toward the radiolabelled beta-adrenergic antagonist [125I]Iodocyanopindolol and a low efficiency of other antagonists such as propranolol, ICI 118551 or CGP 20712A to inhibit cAMP production induced by isoproterenol. Another salient feature shared by the murine and the human beta 3ARs is the very potent effect of the lipolytic compound BRL 37344 on cAMP accumulation and the partial agonistic effect of the beta 1- and beta 2-adrenergic antagonists CGP 12177A, oxprenolol and pindolol. These properties are very close to those ascribed to the atypical beta AR of rodent adipocytes. In addition, Northern blot analyses indicate that the beta 3AR gene is mainly expressed in mouse brown and white adipose tissues, suggesting that the murine beta 3AR described here is the atypical beta AR involved in the control of energy expenditure in fat tissue.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718744      PMCID: PMC453106          DOI: 10.1002/j.1460-2075.1991.tb04940.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  37 in total

Review 1.  Report of the comparative subcommittee for human and mouse homologies.

Authors:  M T Davisson; P A Lalley; J Peters; D P Doolittle; A L Hillyard; A G Searle
Journal:  Cytogenet Cell Genet       Date:  1990

2.  In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon.

Authors:  A Bianchetti; L Manara
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  CGP 12177A modulates brown fat adenylate cyclase activity by interacting with two distinct receptor sites.

Authors:  J G Granneman; C J Whitty
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Structural basis of beta-adrenergic receptor function.

Authors:  C D Strader; I S Sigal; R A Dixon
Journal:  FASEB J       Date:  1989-05       Impact factor: 5.191

7.  Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor.

Authors:  B F O'Dowd; M Hnatowich; M G Caron; R J Lefkowitz; M Bouvier
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

8.  On the disulphide bonds of rhodopsins.

Authors:  S Al-Saleh; M Gore; M Akhtar
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

Review 9.  Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity.

Authors:  B K Kobilka; T S Kobilka; K Daniel; J W Regan; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

10.  An investigation of the beta-adrenoceptor that mediates metabolic responses to the novel agonist BRL28410 in rat soleus muscle.

Authors:  R A Challiss; B Leighton; S Wilson; P L Thurlby; J R Arch
Journal:  Biochem Pharmacol       Date:  1988-03-01       Impact factor: 5.858

View more
  71 in total

1.  beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility.

Authors:  P Varghese; R W Harrison; R A Lofthouse; D Georgakopoulos; D E Berkowitz; J M Hare
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Targeted gene disruption reveals a leptin-independent role for the mouse beta3-adrenoceptor in the regulation of body composition.

Authors:  J P Revelli; F Preitner; S Samec; P Muniesa; F Kuehne; O Boss; J D Vassalli; A Dulloo; J Seydoux; J P Giacobino; J Huarte; C Ody
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M R Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 4.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

Review 5.  A heart-adipose tissue connection in the regulation of energy metabolism.

Authors:  Sheila Collins
Journal:  Nat Rev Endocrinol       Date:  2013-12-03       Impact factor: 43.330

6.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

7.  Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

Authors:  S J Roberts; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

8.  Evidence for fatty acids mediating CL 316,243-induced reductions in blood glucose in mice.

Authors:  Rebecca E K MacPherson; Laura Castellani; Marie-Soleil Beaudoin; David C Wright
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-05       Impact factor: 4.310

9.  Effects on energy utilization of a beta3-adrenergic agonist in rats fed on a cafeteria diet.

Authors:  B Berraondo; A Bonafonte; M P Fernandez-Otero; J A Martinez
Journal:  Eat Weight Disord       Date:  1997-09       Impact factor: 4.652

10.  Transcriptional down-regulation by insulin of the beta 3-adrenergic receptor expression in 3T3-F442A adipocytes: a mechanism for repressing the cAMP signaling pathway.

Authors:  B Fève; K Elhadri; A Quignard-Boulangé; J Pairault
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.